Vimkunya Side Effects

Generic name: chikungunya vaccine, recombinant (cvx 329)

Note: This document provides detailed information about Vimkunya Side Effects associated with chikungunya vaccine, recombinant (cvx 329). Some dosage forms listed on this page may not apply specifically to the brand name Vimkunya.

Applies to chikungunya vaccine, recombinant (cvx 329): intramuscular suspension.

Important warnings This medicine can cause some serious health issues

Use only as directed.

Tell your doctor if you use other medicines or have other medical conditions or allergies.

Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.

Some side effects may occur after the injection. Tell your vaccination provider if you feel dizzy, nauseated, light-headed, itchy, sweaty, or have a headache, chest tightness, back pain, trouble breathing, or swelling in your face.

Common side effects may include:

• pain, redness, swelling, or tenderness where the vaccine was injected;

• headache, weakness, tiredness; or

• muscle pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For healthcare professionals

Applies to chikungunya vaccine, recombinant (cvx 329): intramuscular suspension.

General adverse events

The most commonly reported adverse reactions included injection site pain, fatigue, headache, and myalgia. Local and systemic reactions generally resolved with a median duration of 1 to 2 days.

For defining criteria regarding adverse reactions and additional descriptions of side effects, consult the manufacturer product information.^[Ref]

Gastrointestinal

• Common (1% to 10%): Nausea
• Uncommon (0.1% to 1%): Severe nausea

Local

• Very common (10% or more): Injection site pain (up to 23.7%)
• Uncommon (0.1% to 1%): Injection site swelling at least 25 mm, injection site redness/erythema at least 25 mm
• Rare (0.01% to 0.1%): Severe injection site pain
• Frequency not reported: Injection site redness/erythema greater than 100 mm

Metabolic

• Rare (0.01% to 0.1%): Severe dehydration

Musculoskeletal

• Very common (10% or more): Myalgia/muscle pain (up to 17.6%)
• Common (1% to 10%): Arthralgia/joint pain
• Uncommon (0.1% to 1%): Severe myalgia/muscle pain, severe arthralgia/joint pain

Nervous system

• Very common (10% or more): Headache (up to 18%)
• Uncommon (0.1% to 1%): Severe headache

Other

• Very common (10% or more): Fatigue (up to 19.9%)
• Common (1% to 10%): Chills
• Uncommon (0.1% to 1%): Severe fatigue, fever at least 38C (100.4F), fever at least 39C (102.1F)
• Rare (0.01% to 0.1%): Severe chills

Further information

Vimkunya side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer